The Association of the British Pharmaceutical Industry (ABPI) has launched its consultation to refresh the Code of Practice for the Pharmaceutical Industry for 2021.
“The proposals for the Code would result in the most significant structural change in nearly 30 years and would make a major impact on the way that people interact with the requirements. That is why we are keen for users of the Code to scrutinise the proposals in detail and consider how it will affect the way they work.”
As well as changes to bring the Code into line with its European counterpart coordinated by the European Federation of Pharmaceutical Industries and Associations (EFPIA), the revised Code also seeks to be “future-proof” in its language.
ABPI has asked that pharmaceutical companies submit a single, comprehensive response each, rather than from multiple individuals.